A phase 3 trial of Idorsia’s daridorexant in insomnia patients has met its primary endpoint. The Swiss biotech, which was created through Johnson & Johnson’s takeover of Actelion, also linked the dual orexin receptor antagonist to improvements in daytime performance, sending its share price up 12%.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,